Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) is a multinational healthcare company known for its diversified portfolio of pharmaceuticals, medical devices, and consumer health products. Founded in 1886, it has established itself as a leading player in healthcare, with a global presence and a reputation for innovation and quality in the industry.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 9, 2025 | $1.30 | 2025-08-26 | 2025-08-26 |
| June 10, 2025 | $1.30 | 2025-05-27 | 2025-05-27 |
| March 4, 2025 | $1.24 | 2025-02-18 | 2025-02-18 |
| December 10, 2024 | $1.24 | 2024-11-26 | 2024-11-26 |
| September 10, 2024 | $1.24 | 2024-08-27 | 2024-08-27 |
Dividends Summary
- Johnson & Johnson has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 11 days ago, on September 9, 2025
- The highest dividend payed out to investors during this period was $1.3 per share
- The average dividend paid during this period was $0.74 per share.
Company News
Johnson & Johnson reported promising clinical trial results for a new multiple myeloma treatment combination, with 100% patient response and 85.7% achieving complete response in newly diagnosed patients.
The global topical drugs Contract Development and Manufacturing Organization (CDMO) market is projected to grow from $46.32 billion in 2024 to $136.71 billion by 2034, with a CAGR of 11.43%. Key growth drivers include increasing demand for non-invasive therapies, advancements in drug delivery technologies, and expanding pharmaceutical outsourcing.
A $1,000 investment in Johnson & Johnson 5 years ago would be worth $1,359, underperforming the S&P 500. Despite modest growth, the company shows promise with consistent dividend increases and strong quarterly earnings.
The healthcare sector is experiencing low valuations and potential for a quiet rebound, with improving technical indicators and significant institutional investment despite ongoing political and economic challenges.
This week, J&J and Novartis reported strong Q2 earnings, while Roche's investigational oral weight loss drug showed positive results in an early-stage study. AbbVie also filed for approval of its drug Rinvoq for a new indication.
